title: Interleukin-3 priming in acute myeloid leukaemia patients.
abstract: Several studies have demonstrated that G-CSF, GM-CSF and, in particular, IL-3 can effectively recruit acute myeloid leukaemia (AML) blasts into the cell cycle, resulting in a significant increase in cytosine-arabinoside (Ara-C) mediated cytotoxicity in vitro. Since IL-3 has shown biological and clinical activity, we investigated the cell kinetic effects of rIL-3 and high-dose Ara-C/idarubicin in three patients with refractory AML selected for the presence of chromosome 7 monosomy; this enabled differentiation between the effects of IL-3 on leukaemic and on normal cells. The in vivo administration of rhIL-3 (250 micrograms/m2d s.c. for 6-10d) recruited AML blasts into the cell cycle in two of the three patients, and this effect resulted in an increase in in vitro growth of clonogenic cells (CFU-L) and of their S-phase fraction. The percentage of leukaemic cells with monosomy 7 increased only in the two cases who showed a proliferative response. Normal cells were not recruited, even when rhIL-3 was administered for up to 10 d. In vitro studies showed an increased Ara-C cytotoxicity on clonogenic AML cells, in particular with IL-3 plus GM-CSF, thus confirming the priming effects of IL-3 in the two responding cases. The results of this study suggest that rhIL-3 can selectively recruit leukaemic cells into the cell cycle. Although leukaemic blasts can be sensitized to Ara-C, other mechanisms of primary blast resistance may limit the clinical benefit of kinetic-based approaches.
authors.affiliation: Department of Human Biopathology, University La Sapienza, Rome, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Tafuri
authors.forename: L
authors.initials: L
authors.lastname: de Felice
authors.forename: A
authors.initials: A
authors.lastname: Goodacre
authors.forename: S
authors.initials: S
authors.lastname: Fenu
authors.forename: M T
authors.initials: MT
authors.lastname: Petrucci
authors.forename: T
authors.initials: T
authors.lastname: Valentini
authors.forename: G
authors.initials: G
authors.lastname: Alimena
authors.forename: M C
authors.initials: MC
authors.lastname: Petti
authors.forename: G
authors.initials: G
authors.lastname: Meloni
authors.forename: F
authors.initials: F
authors.lastname: Mandelli
mesh_terms: D000208:Acute Disease; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D002453:Cell Cycle; D003131:Combined Modality Therapy; D016207:Cytokines / Q000494:pharmacology; D006801:Humans; D007377:Interleukin-3 / Q000627:therapeutic use*; D007951:Leukemia, Myeloid / Q000097:blood / Q000473:pathology / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D014407:Tumor Cells, Cultured
chemical_list: D016207:Cytokines; D007377:Interleukin-3; D011994:Recombinant Proteins